Cellbricks’ Post

One day we will have access to universal medicine, just as iPhones are sold globally. This sentence encapsulates the current challenges, possibilities, and policy-making in our pharma, healthcare and life. industry. I spent the first half of the week in Basel attending Swiss Biotech Day, with the highlight being the Capital for Cures Summit! Many of us were eager to leave 2023 behind, but let's consider 2024 as a beacon of new hope for M&A and financing to make a strong comeback. Now is the time to focus on genuine innovation, cutting-edge research, and the development of new biotech products. Although fundraising may present challenges, it's important to remember that every challenge has a silver lining. Here are a few areas where to focus in 2024: -Big Picture and Synergies: How startups and early-stage companies can leverage synergies with other portfolio companies to foster international collaborations. By strengthening global partnerships and exploring new financial models and funding mechanisms aiming to create a robust "Global Village." -Advanced R&D and Manufacturing: Being committed to enhancing research and product development with advanced manufacturing techniques. -Data Management and AI: Integrating artificial intelligence and comprehensive data management systems to boost research outputs and operational efficiencies. -Innovative Financing Exploring innovative financial models and funding mechanisms to support the sustainable growth of biotech ventures.   It was fantastic to present SS&C Intralinks and share the panel with Alan Crowther Marcus Guardian, and Eric de La Fortelle A special shout-out to Sebastian Gensior for making this possible!

Really interesting article from BioSpace today that demonstrates how a fractional executive model helps scaling bioscience businesses reduce their personnel spend and invest that money back into the business IP and product development: https://lnkd.in/exWtHXxk #fractionalexecutive #scaleup #futureisfractional

🔥 𝗨𝗻𝗹𝗼𝗰𝗸 𝘁𝗵𝗲 𝗸𝗲𝘆 𝘁𝗼 𝘄𝗶𝗻𝗻𝗶𝗻𝗴 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿𝘀! 🔥 Top tips from expert Dr. Rebekka Müller!💡 After the summer break is before the next event! We are excitedly looking forward to our next Check-in – it will be the very first event for the Batch #4 teams in Phase 1 after the Bootcamp. In order to properly kick off Phase 1 of the MAX!mize incubator for Max Planck start-ups, which is centred around the #validation and #exploration of the #startup idea for 6 months, there are many valuable #workshops on the agenda. To get things started here and now, we would like to introduce you to Dr. Rebekka Müller. Together with the teams, she will take a closer look at the topics of #CustomerDefinition & #ValueProposition. 🚀 As technology scout at Ascenion GmbH, Rebekka is working together with founders, inventors and scientists from research institutions and university hospitals, helping them advance their projects towards application. She combines deep industry and market experience from her previous marketing roles at Sanofi with profound scientific expertise, holding a PhD in molecular medicine. We interviewed Rebekka in advance and asked her the following question: 𝗜𝗻 𝘆𝗼𝘂𝗿 𝗼𝗽𝗶𝗻𝗶𝗼𝗻, 𝘄𝗵𝗮𝘁 𝗮𝗿𝗲 𝘁𝗵𝗲 𝘁𝗵𝗿𝗲𝗲 𝗺𝗼𝘀𝘁 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗳𝗮𝗰𝘁𝗼𝗿𝘀 𝘁𝗵𝗮𝘁 𝗻𝗲𝗲𝗱 𝘁𝗼 𝗯𝗲 𝗰𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗲𝗱 𝘄𝗶𝘁𝗵 𝗿𝗲𝗴𝗮𝗿𝗱 𝘁𝗼 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿 𝗱𝗲𝗳𝗶𝗻𝗶𝘁𝗶𝗼𝗻 & 𝘃𝗮𝗹𝘂𝗲 𝗽𝗿𝗼𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻? ⬇️ You can find her answer in the slideshow. Would you have expected this?

MedTech Innovator is the largest and highest-performing accelerator of medical technology in the world and the medtech industry’s premiere showcase and competition for innovative medical devices, digital health, and diagnostic companies. 95% of their companies are still in business or have been acquired, raising 30% of the global private funding invested in Medtech last year. The 1st stage is an online application. Afterwards, they run the Medtech Innovator Road Tour where 200 out of 1,400 applicants are invited to participate in one of a series of pitch events. Upfront Diagnostics has been invited to the International Pitch Event held on April 15 in Dublin. (https://lnkd.in/d-tY3aEf) After the event, 50+ companies will be selected to participate in the MedTech Innovator Accelerator. These companies will have access to corporate executives, investors, providers, payers, FDA, NIH, DoD, and other stakeholders. They will join an exclusive peer alumni network of 500+ of the highest-performing medtech startups around the world. In addition to receiving the above benefits, companies will compete for up to $500,000 in non-dilutive cash prizes. Pitch event judges include investors, providers, and senior executives from world-class medtech companies such as Johnson & Johnson, Becton Dickenson, Edwards Lifesciences, Dexcom, Olympus Corporation, Nipro Medical Corporation, and others. #TimeisLife APEX Ventures Cambridge Enterprise

Pricing, Politics and AI To Take Center Stage in 2024 The JP Morgan Healthcare Conference (JPM) reflects the current mood of the life sciences market, and while the tenor was certainly more positive than in 2023, this optimism is dampened by economic uncertainty. Communicating with BioSpace, Daniella Kranjac, founding partner at Dynamk Capital is cautiously optimistic, “There are still a few dark clouds on the horizon, but with therapeutic-enabling technologies, Healthtech and other areas, our experience tends to inform a softer landing.” Not surprisingly, geopolitical and macroeconomic themes continue to play major roles in the market. As interest rates are expected to fall in 2024, and the industry sees more successful public offerings, the potential is there for investment dollars to return to biopharma. https://lnkd.in/g4Zug2Um #aspenalert #biotech #bioprocess

Bibhash Mukhopadhyay participated in a panel discussion at LSX - partnering for Life Science eXecutives World Congress in Boston on September 11, 2024. Revolutionizing the Future: Unveiling the Dynamics of Biotech Investment and Deals in the USA 09:30 - 10:10 BIOTECH LEADERS MORNING KEYNOTE PLENARY PANEL After a blustery few years, are the winds finally changing for biotech? Poised for growth in 2024, the biotech industry, driven by continued scientific breakthroughs, changing market dynamics, and the impending patent cliff is set to be one of the biggest years in biotech since the onset of the pandemic. With the door opening to generic competition as blockbuster drugs lose patent protection and big pharma likely to turn to biotech acquisition to restock pipelines, how are the experts viewing the current state of the market as we creep towards the final quarter of 2024? • What healthcare trends are shaping the industry, and how is the biotech financing landscape evolving? • What fresh challenges have we seen thus far in 2024? • How does the US market compare on a global scale, and how can the industry continue to work towards a full market recovery? • Future outlook for the biotech capital markets Participants Jim MacKrell - VP Lilly Venture Science, Eli Lilly Issi Rozen - General Partner, Google Ventures Richard Kivel - CEO, Graybella Capital Bibhash Mukhopadhyay - Managing Partner, Sound Bioventures Maha Radhakrishnan- Executive Partner, Sofinnova Investments Moderator: Chris Jeffers - SVP, Life Sciences, Brown Rudnick #biotech #biotechnology #healthcare Sound Bioventures

🚀 Discovering cutting-edge BioTech solutions? Remember, success isn't just about the idea; it's about infrastructure too! NewVale is investing in the foundations that power drug startups, ensuring the path to innovative treatments is as efficient as the science behind them. 🧪 From tailored machine learning software to essential manufacturing services, NewVale backs the unsung heroes of pharma services. For my executive network in MedTech, HealthTech, BioTech and pharma: Keep an eye out for the next step in optimizing the journey from lab to patient! Your next partnership could be with a firm that's strengthening the very backbone of our industry. #Biotech #PharmaInfrastructure #InnovationInvestment

What a great event that was! We are still thrilled with the success of our first #biotechnology #conference: BioM's #BayOConnect! Bavaria showed its great potential of #ArtificialIntelligence and #data in medicine - uniting players from all areas of Bavarian and #international biotechnology. With 320 participants, 250 #partnering meetings, 15 #startup pitches, 20 exhibitors and over 30 sponsors and partners, BioM Biotech Cluster Development GmbH successfully promoted the new hotspot for #networking in the #biotech industry. Big players as Roche Deutschland, Google, Amazon Web Services (AWS) and NVIDIA, hidden champions and brilliant start-ups showed developments and innovative applications of #AI and big data for a new medicine - under watchful eyes of experts and #investors. Already mark you calendar! #BioM's BayOConnect will be back on stage next year on 👉 1-2 July 2025 👈! For impressions and if you want to know who won this year's BayOConnect #StartupAward (sponsored by Amazon Web Services) - here is a recap of this year's event. ➡️ https://lnkd.in/epGGGwiS #savethedate #Munich #biotechconference #biotechinnovation #innovationinBavaria #lifescience #research #funding #investment #venturecapital

The #MarylandMedTech Summit started off hot yesterday, with an expert panel discussing some trends in MedTech. Highlights from the informative conversation between George Davis, Kyparissia (Kyp) Sirinakis, Robert Storey, Youseph Yazdi, Henry Brem, M.D. Private capital is more risk-tolerant and better for innovation than Public funding in the long run, but it might be a tough fundraising environment in Private markets for the next 12 months. 😬 There's excitement about the potential for integrating medical devices and biology for applications like continuously monitoring the efficacy of drugs, but we have to remain focused on improving access to healthcare by developing devices that deliver real medical value at reasonable prices. Sorry, lasers... As an ecosystem, we also want to retain the amazing local technical, medical, and entrepreneurship talent in the region by increasing support and mentorship resources for startups through incubators, accelerators, and access to capital. Thanks to Stefanie Trop Ph.D., William Bentley, and Martha Wang, Ph.D. for organizing the Summit!

San Diego investor event: Aquillius Medical Devices & Diagnostics Symposium, taking place on Wednesday, May 15th, from 12:30 PM to 7:00 PM. This exclusive event brings together leading industry experts, groundbreaking startups, and prominent investors like yourself. Here's what you can expect: Expert Insights: Gain valuable knowledge from renowned speakers on topics critical to medtech success, including design for manufacturing, intellectual property protection, regulatory navigation, and fostering successful startups. Early Access to Innovation: Witness the future of healthcare firsthand as promising Aquillius incubees showcase their innovative medical device and diagnostic solutions during a dedicated startup showcase. Networking Opportunities: Connect and build relationships with other investors, entrepreneurs, and industry leaders shaping the medical technology landscape. This is a unique opportunity to: Identify promising investment opportunities in the medtech sector. Gain valuable insights from leading experts. Network with a community of like-minded investors and industry professionals. Space is limited, so RSVP today! Medical Devices Symposium (Investor Registration) Tickets, Wed, May 15, 2024 at 12:30 PM | https://lnkd.in/gjWDU9pz